NAMS Menopause Certification Exam Updated 2026
| 300+ Practice Questions & Verified Answers |
Comprehensive Menopause Society Certified
Practitioner Study Guide, Midlife Women's Health
Exam Prep, Hormone Therapy, Perimenopause,
Postmenopause, Vasomotor Symptoms, Bone Health,
Genitourinary Syndrome of Menopause (GSM),
Women's Health, Evidence-Based Clinical Practice,
Detailed Rationales
Question 1: A 52-year-old perimenopausal woman reports heavy menstrual
bleeding occurring every 21 days. Her hemoglobin is 10.2 g/dL. What is the
most appropriate initial diagnostic step to evaluate the etiology of her
abnormal uterine bleeding?
A. Endometrial biopsy
B. Transvaginal ultrasound
C. Hysteroscopy with directed biopsy
D. Serum pregnancy test
CORRECT ANSWER: B. Transvaginal ultrasound
Rationale: The initial evaluation of abnormal uterine bleeding in a perimenopausal
woman should begin with a transvaginal ultrasound to assess endometrial thickness,
uterine size, and the presence of fibroids or polyps. An endometrial biopsy is indicated if
the endometrial stripe is >4-5 mm. Hysteroscopy is a secondary or adjunctive
procedure. A pregnancy test is essential but does not evaluate the structural etiology.
Question 2: Which of the following is the primary mechanism of action of
ospemifene for the treatment of vulvovaginal atrophy?
A. Estrogen receptor agonist in vaginal tissue
B. Selective estrogen receptor modulator (SERM) with tissue-specific effects
C. Androgen receptor antagonist
D. Aromatase inhibitor
CORRECT ANSWER: B. Selective estrogen receptor modulator (SERM) with
tissue-specific effects
Rationale: Ospemifene is a SERM that acts as an estrogen agonist in vaginal epithelium,
improving dyspareunia and vaginal dryness, while maintaining antagonistic effects on
breast and endometrial tissue. It is not a pure agonist, androgen antagonist, or
aromatase inhibitor.
,Question 3: A 48-year-old woman has an intact uterus and is requesting
menopausal hormone therapy (MHT) for severe vasomotor symptoms. Which
regimen is associated with the lowest risk of endometrial hyperplasia?
A. Oral conjugated equine estrogens 0.625 mg daily
B. Oral estradiol 1 mg daily
C. Continuous combined estradiol 1 mg / norethindrone 0.5 mg daily
D. Transdermal estradiol 0.05 mg daily
CORRECT ANSWER: C. Continuous combined estradiol 1 mg / norethindrone
0.5 mg daily
Rationale: In women with an intact uterus, a continuous combined estrogen-progestin
regimen is required to prevent endometrial hyperplasia. This regimen suppresses
endometrial proliferation and is associated with a lower risk of hyperplasia compared to
unopposed estrogen or sequential regimens.
Question 4: What is the most significant risk reduction benefit associated with
the use of menopausal hormone therapy when initiated within 10 years of
menopause?
A. Reduction in breast cancer mortality
B. Reduction in coronary heart disease events
C. Reduction in venous thromboembolism
D. Reduction in endometrial cancer
CORRECT ANSWER: B. Reduction in coronary heart disease events
Rationale: The "timing hypothesis" suggests that MHT initiated early in menopause
reduces the risk of coronary heart disease. The WHI data indicated a lower risk of CHD
in women aged 50-59 or those within 10 years of menopause onset. There is no
reduction in VTE or breast cancer mortality, and endometrial cancer risk is mitigated by
progestin use.
Question 5: Which of the following is a contraindication to the use of systemic
menopausal hormone therapy?
A. History of migraines with aura
B. History of gallbladder disease
C. History of endometriosis
D. History of estrogen receptor-positive breast cancer
CORRECT ANSWER: D. History of estrogen receptor-positive breast cancer
Rationale: A personal history of estrogen receptor-positive breast cancer is an absolute
contraindication to systemic MHT due to the risk of stimulating residual or recurrent
,disease. Migraines with aura, gallbladder disease, and endometriosis are relative
contraindications that require careful risk-benefit analysis.
Question 6: A 55-year-old woman on oral estradiol 1 mg and micronized
progesterone 200 mg daily reports breast tenderness and breakthrough
bleeding. What is the most appropriate management strategy?
A. Discontinue hormone therapy immediately
B. Switch to a lower dose of estradiol
C. Perform an endometrial biopsy
D. Switch to a transdermal estradiol patch
CORRECT ANSWER: C. Perform an endometrial biopsy
Rationale: Breakthrough bleeding in a woman on continuous combined MHT,
especially after the first 6 months, warrants an endometrial evaluation to rule out
hyperplasia or malignancy. Breast tenderness is a common side effect, but the bleeding
requires investigation before adjusting the regimen.
Question 7: What is the recommended screening interval for bone mineral
density in a 60-year-old postmenopausal woman with osteopenia who is not
on pharmacologic therapy?
A. Every 1 year
B. Every 2-3 years
C. Every 5 years
D. Every 10 years
CORRECT ANSWER: B. Every 2-3 years
Rationale: For postmenopausal women with osteopenia (T-score between -1.0 and -
2.5), repeat BMD testing is typically recommended every 2-3 years to monitor for
progression to osteoporosis. More frequent testing is not usually necessary unless
significant risk factors change.
Question 8: Which non-hormonal medication is FDA-approved for the
treatment of moderate-to-severe vasomotor symptoms associated with
menopause?
A. Gabapentin
B. Fluoxetine
C. Paroxetine
D. Venlafaxine
CORRECT ANSWER: C. Paroxetine
, Rationale: Paroxetine (specifically the low-dose formulation) is the only non-hormonal
medication FDA-approved for the treatment of vasomotor symptoms. While gabapentin
and venlafaxine are effective off-label, they are not FDA-approved for this specific
indication.
Question 9: A 49-year-old woman with a history of hysterectomy is
experiencing severe hot flashes. She has a history of deep vein thrombosis
(DVT) 5 years ago. What is the safest therapeutic option?
A. Oral conjugated equine estrogens
B. Transdermal estradiol
C. Oral estradiol
D. Estradiol vaginal ring
CORRECT ANSWER: B. Transdermal estradiol
Rationale: In a woman with a history of DVT, the transdermal route of estrogen
administration is preferred as it avoids first-pass hepatic metabolism and does not
increase clotting factors, thereby lowering the risk of VTE recurrence compared to oral
estrogens. The vaginal ring is for local symptoms.
Question 10: What is the mechanism by which selective serotonin reuptake
inhibitors (SSRIs) reduce menopausal hot flashes?
A. Central serotonin modulation of the thermoregulatory center
B. Peripheral vasoconstriction
C. Estrogen receptor agonism
D. Inhibition of norepinephrine reuptake
CORRECT ANSWER: A. Central serotonin modulation of the thermoregulatory
center
Rationale: SSRIs reduce hot flashes by modulating serotonin neurotransmission in the
hypothalamus, which plays a role in thermoregulation and vasomotor instability. They
do not have estrogenic activity or direct peripheral vasoconstrictive effects.
Question 11: Which of the following is the most sensitive marker for ovarian
reserve in a perimenopausal woman?
A. Follicle-stimulating hormone (FSH)
B. Luteinizing hormone (LH)
C. Anti-Müllerian hormone (AMH)
D. Estradiol (E2)
CORRECT ANSWER: C. Anti-Müllerian hormone (AMH)
| 300+ Practice Questions & Verified Answers |
Comprehensive Menopause Society Certified
Practitioner Study Guide, Midlife Women's Health
Exam Prep, Hormone Therapy, Perimenopause,
Postmenopause, Vasomotor Symptoms, Bone Health,
Genitourinary Syndrome of Menopause (GSM),
Women's Health, Evidence-Based Clinical Practice,
Detailed Rationales
Question 1: A 52-year-old perimenopausal woman reports heavy menstrual
bleeding occurring every 21 days. Her hemoglobin is 10.2 g/dL. What is the
most appropriate initial diagnostic step to evaluate the etiology of her
abnormal uterine bleeding?
A. Endometrial biopsy
B. Transvaginal ultrasound
C. Hysteroscopy with directed biopsy
D. Serum pregnancy test
CORRECT ANSWER: B. Transvaginal ultrasound
Rationale: The initial evaluation of abnormal uterine bleeding in a perimenopausal
woman should begin with a transvaginal ultrasound to assess endometrial thickness,
uterine size, and the presence of fibroids or polyps. An endometrial biopsy is indicated if
the endometrial stripe is >4-5 mm. Hysteroscopy is a secondary or adjunctive
procedure. A pregnancy test is essential but does not evaluate the structural etiology.
Question 2: Which of the following is the primary mechanism of action of
ospemifene for the treatment of vulvovaginal atrophy?
A. Estrogen receptor agonist in vaginal tissue
B. Selective estrogen receptor modulator (SERM) with tissue-specific effects
C. Androgen receptor antagonist
D. Aromatase inhibitor
CORRECT ANSWER: B. Selective estrogen receptor modulator (SERM) with
tissue-specific effects
Rationale: Ospemifene is a SERM that acts as an estrogen agonist in vaginal epithelium,
improving dyspareunia and vaginal dryness, while maintaining antagonistic effects on
breast and endometrial tissue. It is not a pure agonist, androgen antagonist, or
aromatase inhibitor.
,Question 3: A 48-year-old woman has an intact uterus and is requesting
menopausal hormone therapy (MHT) for severe vasomotor symptoms. Which
regimen is associated with the lowest risk of endometrial hyperplasia?
A. Oral conjugated equine estrogens 0.625 mg daily
B. Oral estradiol 1 mg daily
C. Continuous combined estradiol 1 mg / norethindrone 0.5 mg daily
D. Transdermal estradiol 0.05 mg daily
CORRECT ANSWER: C. Continuous combined estradiol 1 mg / norethindrone
0.5 mg daily
Rationale: In women with an intact uterus, a continuous combined estrogen-progestin
regimen is required to prevent endometrial hyperplasia. This regimen suppresses
endometrial proliferation and is associated with a lower risk of hyperplasia compared to
unopposed estrogen or sequential regimens.
Question 4: What is the most significant risk reduction benefit associated with
the use of menopausal hormone therapy when initiated within 10 years of
menopause?
A. Reduction in breast cancer mortality
B. Reduction in coronary heart disease events
C. Reduction in venous thromboembolism
D. Reduction in endometrial cancer
CORRECT ANSWER: B. Reduction in coronary heart disease events
Rationale: The "timing hypothesis" suggests that MHT initiated early in menopause
reduces the risk of coronary heart disease. The WHI data indicated a lower risk of CHD
in women aged 50-59 or those within 10 years of menopause onset. There is no
reduction in VTE or breast cancer mortality, and endometrial cancer risk is mitigated by
progestin use.
Question 5: Which of the following is a contraindication to the use of systemic
menopausal hormone therapy?
A. History of migraines with aura
B. History of gallbladder disease
C. History of endometriosis
D. History of estrogen receptor-positive breast cancer
CORRECT ANSWER: D. History of estrogen receptor-positive breast cancer
Rationale: A personal history of estrogen receptor-positive breast cancer is an absolute
contraindication to systemic MHT due to the risk of stimulating residual or recurrent
,disease. Migraines with aura, gallbladder disease, and endometriosis are relative
contraindications that require careful risk-benefit analysis.
Question 6: A 55-year-old woman on oral estradiol 1 mg and micronized
progesterone 200 mg daily reports breast tenderness and breakthrough
bleeding. What is the most appropriate management strategy?
A. Discontinue hormone therapy immediately
B. Switch to a lower dose of estradiol
C. Perform an endometrial biopsy
D. Switch to a transdermal estradiol patch
CORRECT ANSWER: C. Perform an endometrial biopsy
Rationale: Breakthrough bleeding in a woman on continuous combined MHT,
especially after the first 6 months, warrants an endometrial evaluation to rule out
hyperplasia or malignancy. Breast tenderness is a common side effect, but the bleeding
requires investigation before adjusting the regimen.
Question 7: What is the recommended screening interval for bone mineral
density in a 60-year-old postmenopausal woman with osteopenia who is not
on pharmacologic therapy?
A. Every 1 year
B. Every 2-3 years
C. Every 5 years
D. Every 10 years
CORRECT ANSWER: B. Every 2-3 years
Rationale: For postmenopausal women with osteopenia (T-score between -1.0 and -
2.5), repeat BMD testing is typically recommended every 2-3 years to monitor for
progression to osteoporosis. More frequent testing is not usually necessary unless
significant risk factors change.
Question 8: Which non-hormonal medication is FDA-approved for the
treatment of moderate-to-severe vasomotor symptoms associated with
menopause?
A. Gabapentin
B. Fluoxetine
C. Paroxetine
D. Venlafaxine
CORRECT ANSWER: C. Paroxetine
, Rationale: Paroxetine (specifically the low-dose formulation) is the only non-hormonal
medication FDA-approved for the treatment of vasomotor symptoms. While gabapentin
and venlafaxine are effective off-label, they are not FDA-approved for this specific
indication.
Question 9: A 49-year-old woman with a history of hysterectomy is
experiencing severe hot flashes. She has a history of deep vein thrombosis
(DVT) 5 years ago. What is the safest therapeutic option?
A. Oral conjugated equine estrogens
B. Transdermal estradiol
C. Oral estradiol
D. Estradiol vaginal ring
CORRECT ANSWER: B. Transdermal estradiol
Rationale: In a woman with a history of DVT, the transdermal route of estrogen
administration is preferred as it avoids first-pass hepatic metabolism and does not
increase clotting factors, thereby lowering the risk of VTE recurrence compared to oral
estrogens. The vaginal ring is for local symptoms.
Question 10: What is the mechanism by which selective serotonin reuptake
inhibitors (SSRIs) reduce menopausal hot flashes?
A. Central serotonin modulation of the thermoregulatory center
B. Peripheral vasoconstriction
C. Estrogen receptor agonism
D. Inhibition of norepinephrine reuptake
CORRECT ANSWER: A. Central serotonin modulation of the thermoregulatory
center
Rationale: SSRIs reduce hot flashes by modulating serotonin neurotransmission in the
hypothalamus, which plays a role in thermoregulation and vasomotor instability. They
do not have estrogenic activity or direct peripheral vasoconstrictive effects.
Question 11: Which of the following is the most sensitive marker for ovarian
reserve in a perimenopausal woman?
A. Follicle-stimulating hormone (FSH)
B. Luteinizing hormone (LH)
C. Anti-Müllerian hormone (AMH)
D. Estradiol (E2)
CORRECT ANSWER: C. Anti-Müllerian hormone (AMH)
